Welcome to our dedicated page for Exicure news (Ticker: XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure stock.
Exicure Inc (XCUR) is a pioneering biotechnology company developing nucleic acid therapies through its proprietary Spherical Nucleic Acid (SNA) platform. This page serves as the definitive source for verified news and press releases related to the company’s advancements in immunomodulatory treatments, gene silencing innovations, and therapeutic applications across oncology, inflammatory disorders, and neurological conditions.
Access real-time updates on Exicure’s clinical progress, regulatory milestones, and strategic partnerships. Our curated collection includes announcements on SNA technology breakthroughs, trial results, and research collaborations, providing stakeholders with a comprehensive view of the company’s scientific and operational trajectory.
Key content categories include clinical trial updates, regulatory filings, technology licensing agreements, and peer-reviewed research highlights. Each update is structured to help investors and researchers assess Exicure’s position in the competitive biotech landscape while maintaining strict adherence to factual reporting standards.
Bookmark this page for streamlined access to Exicure’s latest developments, and check back regularly for authoritative insights into one of biotechnology’s most innovative nucleic acid delivery platforms.
Exicure, Inc. (NASDAQ: XCUR) announced that the FDA has granted Orphan Drug Designation for its candidate cavrotolimod (AST-008) targeting Merkel cell carcinoma (MCC). This designation is a significant step towards addressing unmet medical needs for MCC patients. Exicure previously received Fast Track designations for cavrotolimod for MCC and cutaneous squamous cell carcinoma (CSCC). Cavrotolimod is currently in Phase 1b/2 clinical trials, showing promising anti-tumor activity with no serious adverse events reported thus far.
Exicure, Inc. (Nasdaq: XCUR) announced that CEO David Giljohann will present at the 2021 H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available for registered attendees to view on-demand starting March 9, 2021, at 7:00 AM EST, and it will be archived for 90 days. Exicure is a biotechnology firm focusing on gene regulatory therapies using its proprietary Spherical Nucleic Acid (SNA) technology, currently in preclinical development for Friedreich’s ataxia and advancing in clinical trials for solid tumors.
Exicure, Inc. (Nasdaq: XCUR) has announced its participation in 1x1 meetings with institutional investors at the 10th Annual SV Leerink Global Healthcare Conference from February 24 to 26, 2021. The company focuses on gene regulatory and immunotherapeutic drug development using its proprietary Spherical Nucleic Acid (SNA™) technology. Exicure is currently advancing its drug candidate XCUR-FXN for Friedreich’s ataxia and conducting a Phase 1b/2 trial for AST-008 in advanced solid tumors. The company is headquartered in Chicago, IL, with an office in Cambridge, MA.
Exicure, Inc. (Nasdaq: XCUR) announced that CEO David Giljohann will present at the BIO CEO & Investor Digital Conference from February 16-18, 2021. The presentation will be available for on-demand viewing for registered attendees beginning February 15, 2021. Attendees can schedule 1x1 meetings with Exicure during the conference. With a focus on gene regulatory and immunotherapeutic drugs, Exicure is developing therapeutics targeting neurological and inflammatory diseases utilizing its proprietary Spherical Nucleic Acid (SNA) technology.
Exicure, Inc. (NASDAQ: XCUR) has received Fast Track designations from the FDA for cavrotolimod (AST-008) targeting advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma, both refractory to prior therapies. Cavrotolimod enhances immune responses and is currently in a Phase 1b/2 trial, showing a 21% overall response rate in evaluable patients, including durable responses exceeding six months. No serious adverse events were reported, and significant immune cell activation was observed. This designation highlights the urgent need for novel therapies in these cancer types.
Exicure, Inc. (NASDAQ: XCUR) has appointed James Sulat to its Board of Directors, bringing extensive biopharmaceutical experience. Sulat has held leadership roles at various firms and currently serves on the boards of Valneva SE and Arch Therapeutics. His background in business development and finance is expected to support Exicure's growth. Additionally, Jay Venkatesan has resigned from the Board, effective December 29, 2020. The company focuses on gene regulatory therapies targeting cancer and genetic disorders using its proprietary SNA™ technology, with its lead program in a Phase 1b/2 trial.
Exicure, Inc. (NASDAQ: XCUR) will host a virtual R&D Day on January 7, 2021, to discuss its neuroscience pipeline, focusing on its lead program for Friedreich’s Ataxia (FA). The company reported that XCUR-FXN has moved into IND-enabling studies, with updates on other preclinical programs targeting SCN9A for neuropathic pain and CLN3 for Batten Disease. Exicure will showcase CNS biodistribution studies of its SNA™ therapeutics. Despite the absence of therapies for FA, the meeting aims to engage stakeholders in discussions about future clinical developments.
Exicure, Inc. (Nasdaq: XCUR) announced that CEO David Giljohann will present at the HC Wainwright Virtual BIOCONNECT Conference from January 11-14, 2021. The presentation will be available on-demand starting January 11 at 6:00 AM EST via the conference link. Exicure focuses on gene regulatory and immunotherapeutic drugs utilizing its proprietary Spherical Nucleic Acid (SNA™) technology. Currently, the company is developing candidates for Friedreich’s ataxia and has a drug in a Phase 1b/2 clinical trial for advanced solid tumors.
Exicure, Inc. (NASDAQ: XCUR) has announced a virtual R&D Day on January 7, 2021, from 09:00 am to 10:30 am ET. This event will showcase the company's neuroscience pipeline, particularly its lead program targeting Friedreich’s Ataxia, which has moved into IND-enabling studies. Participants include Dr. Susan Perlman and Jennifer Farmer, who will discuss advancements in the program. Exicure is focused on developing therapeutics using its proprietary SNA technology to address various conditions, including genetic disorders.
Exicure, Inc. (Nasdaq: XCUR) has strengthened its intellectual property portfolio with the issuance of two new patents and the allowance of a patent application related to its therapeutic candidate, cavrotolimod. The new patents (No. 10,792,251 and No. 10,837,018) cover innovative spherical nucleic acid constructs for cancer treatment. CEO David Giljohann expressed enthusiasm about cavrotolimod, currently in Phase 2 clinical trials for Merkel cell carcinoma and cutaneous squamous cell carcinoma, indicating its potential to address unmet medical needs in these rare skin cancers.
